Page last updated: 2024-12-05

dicarbethoxydihydrocollidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dicarbethoxydihydrocollidine: 1,4-Dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid diethyl ester. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3,5-diethoxycarbonyl-1,4-dihydrocollidine : A dihydropyridine that is 2,4,6-trimethyl-1,4-dihydropyridine substituted by ethoxycarbonyl groups at positions 3 and 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12446
CHEMBL ID3409638
CHEMBL ID3189958
CHEBI ID83605
SCHEMBL ID3503405
MeSH IDM0006262

Synonyms (65)

Synonym
3,5-dicarbethoxy-1,4-dihydro-2,4,6-trimethylpyridine
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,4,6-trimethyl-, 3,5-diethyl ester
chembl3409638 ,
chebi:83605 ,
bdbm50073946
MLS000554355
2,4,6-trimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester
smr000146672
nsc49528
nsc-49528
OPREA1_040271
3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-collidine
einecs 211-188-0
diethyl 1,4-dihydro-2,4,6-trimethylpyridine-3,5-dicarboxylate
nsc 8910
nsc 49528
ddc (van)
3,5-bis(ethoxycarbonyl)-1,4-dihydrocollidine
dicarbethoxydihydrocollidine
3,5-diethoxycarbonyl-1,4-dihydrocollidine
3,5-dicarbethoxy-1,4-dihydrocollidine
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,4,6-trimethyl-, diethyl ester
1,4-dihydro-3,5-dicarbethoxycollidine
632-93-9
3,4-dihydrocollidine
3, 1,4-dihydro-2,4,6-trimethyl-, diethyl ester
nsc-8910
ddc (porphyrinogen)
nsc8910
mls000766200 ,
1,5-dicarbethoxycollidine
diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate
1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid, diethyl ester
diethyl 1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate, 99%
MAYBRIDGE1_000106
MIXCOM1_000194
SR-01000635388-1
1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid diethyl ester
diethyl 1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate
D0558
A834316
NCGC00246343-01
NCGC00246343-02
HMS2564I21
AKOS005208036
3,5-diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CCG-45634
FT-0614525
SCHEMBL3503405
DTXSID6060898
3,5-diethoxycarbonyl-1,4-dihydro-s-collidine
diethyl 2,4,6-trimethyl-1,4-dihydro-3,5-pyridinedicarboxylate #
CDVAIHNNWWJFJW-UHFFFAOYSA-N
CHEMBL3189958
mfcd00005950
GS-5680
diethyl 1,4-dihydro-2,4,6-trimethyl pyridine-3,5-dicarboxylate
Q27157006
ferricacetylacetonate
AMY23498
nsc 8910;ddc
F11713
diethyl2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CS-0067585
PD063982

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We investigated the impact of genetic loss of either K8 or K18 on liver homeostasis under toxic stress with the hypothesis that K8 and K18 exert different functions."( Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model.
Denk, H; Fickert, P; Haybaeck, J; Hesse, M; Kolbe, T; Magin, TM; Müller, H; Stumptner, C; Thueringer, A; Trauner, M; Tsybrovskyy, O; Zatloukal, K, 2012
)
0.38
" Our observations clearly demonstrate principally different mechanisms for acute and chronic toxic damage."( Transition between acute and chronic hepatotoxicity in mice is associated with impaired energy metabolism and induction of mitochondrial heme oxygenase-1.
Abuja, PM; Kratky, D; Lackner, C; Nikam, A; Patankar, JV; Schöck, E; Zatloukal, K, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" Fluorescence of 3-amino-4-(N-methylamino)-2',7'-difluorofluorescein (DAF-FM) and dihydroethidium (DHE) were used for quantification of nitric oxide bioavailability and superoxide concentration, respectively."( Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration rate.
Lai, EY; Liu, ZZ; Patzak, A; Perlewitz, A; Persson, PB; Sendeski, MM; Viegas, VU, 2012
)
0.38
" Decreased nitric oxide bioavailability and increased concentration of superoxide explain the increased tone and reactivity in afferent arterioles perfused with iodixanol."( Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration rate.
Lai, EY; Liu, ZZ; Patzak, A; Perlewitz, A; Persson, PB; Sendeski, MM; Viegas, VU, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" However, the increase in CCl(4) dosage significantly worsened survival."( Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation.
Chang, ML; Chang, PY; Chen, JC; Yeh, CT, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
hepatic steatosis inducing agentAny hepatotoxic agent capable of inducing liver steatosis or fatty liver disease.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dihydropyridine
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency112.20200.044717.8581100.0000AID485294
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.83260.177814.390939.8107AID2147
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
WRNHomo sapiens (human)Potency22.38720.168331.2583100.0000AID651768
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency19.95260.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency23.10930.004611.374133.4983AID624296
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency112.20203.981146.7448112.2020AID720711
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Oligo-1,6-glucosidase IMA1Saccharomyces cerevisiae S288CIC50 (µMol)50.00009.37009.37009.3700AID1198845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1198845Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate preincubated for 15 mins measured up to 30 mins by spectrophotometry2015European journal of medicinal chemistry, May-05, Volume: 95Synthesis of diethyl 4-substituted-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylates as a new series of inhibitors against yeast α-glucosidase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (319)

TimeframeStudies, This Drug (%)All Drugs %
pre-199088 (27.59)18.7374
1990's41 (12.85)18.2507
2000's56 (17.55)29.6817
2010's106 (33.23)24.3611
2020's28 (8.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.89 (24.57)
Research Supply Index5.79 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (1.83%)6.00%
Case Studies1 (0.31%)4.05%
Observational0 (0.00%)0.25%
Other320 (97.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]